title: Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer.
abstract: The optimal role of paclitaxel in the treatment of epithelial ovarian cancer has not been determined. Dose intense paclitaxel therapy is safe and often recommended as second-line treatment for platinum resistant ovarian cancer. Retreatment with a higher dose-intense schedule of paclitaxel is feasible and patients who had a prior dose of 135 mg/m2 or paclitaxel free interval of at least six months may respond. Sensitivity to initial doses and a prolonged paclitaxel-free interval are predictors of a successful reinduction. We report 10 patients who had paclitaxel as second-line treatment and were later retreated with paclitaxel. Three of these patients had a partial response (30%; 95% CI 6-66%). All but one patient had platinum resistant disease. Initial dose and the best response to initial paclitaxel were assessed in relation to reinduction response. Patients with at least a six-month paclitaxel-free interval and previously low dose paclitaxel (135 mg/m2), or a complete response with high dose paclitaxel (250 mg/m2) may respond to high dose paclitaxel retreatment. Prospective trials of paclitaxel retreatment are warranted.
authors.affiliation: Chulalongkorn University Hospital, Bangkok, Thailand.
authors.forename: D
authors.initials: D
authors.lastname: Tresukosol
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C
authors.initials: C
authors.lastname: Gonzales de Leon
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: R S
authors.initials: RS
authors.lastname: Freedman
authors.forename: R
authors.initials: R
authors.lastname: Mante
authors.forename: M
authors.initials: M
authors.lastname: Hord
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel